Good afternoon, ladies and gentlemen. Welcome to the Nanalysis Scientific Q1 2024 conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 29, 2024. I would now like to turn the conference over to Matthew Selinger, Investor Relations. Please go ahead. Thank you, operator, and welcome everyone to Nanalysis Scientific's first quarter 2024 conference call. Before we begin, I would like to remind everyone that our remarks and responses to your questions today will contain forward-looking statements that are based on the current expectations of management. These assumptions involve inherent risks and uncertainties that could cause actual results to differ materially from our responses. Certain material factors and assumptions were considered and applied in making the forward-looking statements. These risk factors are included in our filings for the year ended December 31, 2023. Forward-looking statements on this call may include, but are not limited to, statements and comments with respect to future growth of the company's business, the ability to graduate to a senior exchange, the company's acquisition strategy, the ability to develop future products, and the possible associated results. The company's actual performance and financial results in the future could differ materially from any estimates or projections of future performance implied by the forward-looking statements. The forward-looking statements made on this call speak only as of today, and Nanalysis Scientific assumes no obligation to update any forward-looking information as a result of new information, future events, or otherwise, except as expressly required by applicable law. So for additional information, I encourage everyone to review our public filings and press releases, which are posted on the SEDAR+ filing system at www.sedarplus.ca, which is S-E-D-A-R-P-L-U-S dot ca. On the call with me today are Nanalysis founder and CEO, Mr. Sean Krakiwsky, and Nanalysis CFO, Mr. Randall McRae. So with that, and at this point in the call, I would like to turn the call over to Randall McRae. Randall? Thanks, Matthew. It's a pleasure to join and speak with everyone on the call today. I'm now going to dive into the financial results for the quarter ending on March 31, 2024. All amounts referenced are in Canadian dollars. Financial highlights for the three months ended March 31, 2024 include: for the three months ended, the company reported consolidated revenue of CAD 11.2 million, an increase of CAD 6.5 million, or 139% from the comparative period in 2023. This includes approximately CAD 4.2 million in product sales and CAD 6.9 million of revenues related to services. CAD 2.2 million of service revenue came from flow-through inventory associated with the company's airport security maintenance contract, in which the company provides purchasing and resale to the customer at cost, with the company billing a fixed charge for the service. This revenue can vary widely quarter over quarter and may be significantly lower in future quarters. Gross margin percentage on product sales was 47% for the three months ended March 31, 2024. Improvement in gross margin percentage for benchtop NMR is materializing as sales have improved in the second half of last year and continued into the first quarter of this year. In addition, reductions in manufacturing labor late in Q2 2023 have begun to positively affect margins. Security service gross margin percentage in the quarter was 8% versus -76% in the prior year comparative period, as the company has completed its full transition of 100% of airport service to its control from the incumbent provider, and now expects to increase revenue and drive efficiency on the projects through 2024. EBITDA loss for the three months ended March 31, 2024, was CAD 362,000 versus an EBITDA loss of CAD 3.5 million in the same period last year. This improvement was driven by increased product sales, full transition of airports to the company's control, and cost reduction initiatives. Net loss, which includes non-cash items for the three months ended, was CAD 2.5 million, as compared to the three-month loss for March 31, 2023, of CAD 4.3 million. The company had approximately CAD 1.7 million cash on hand, an undrawn credit facility of CAD 3.2 million, and working capital of CAD 6.3 million as of March 31, 2024. As noted above, we booked considerable revenues from flow-through parts this quarter related to our security services contract. As we've stated before, these will tend to be lumpy for the life of this contract. This quarter was particularly large. As such, we have now broken out these in a table in the press release. That being said, we are very happy to report that our service business gross margins turned positive this last quarter and was EBITDA positive. We expect these margins to continue to improve as the capital-intensive portion of this project is over, and we'll see reductions in training costs going forward. We feel we're in a good financial position and are poised to now reap benefits of this long-term project. Additionally, we continue to look for opportunities where we can now leverage our trained workforce. Finally, we continue to see the results from our cost reduction plan, which started in the second quarter of 2023. The goal was to better align our resources and reduce our fixed costs. We are seeing these manifest in improved gross margin percentages, which began in the fourth quarter of 2023. The company continues to evaluate other fixed cost reductions to further increase annualized cost savings and has continued to apply cost reduction measures in 2024. I'll reiterate our goals for the year, which are to continue to grow revenue as well as our margins by focusing on positive EBITDA and profitability for the company as a whole. I'm happy and encouraged by the progress we're making here. With that, I'd like to now turn the call over to our founder and CEO, Sean Krakiwsky. ... Thank you very much, Randall. To build on what Randall said, I am very happy to report another record revenue quarter of over CAD 11 million in top-line results. We are starting to see the makings of a solid scientific instrumentation company with both products based on world-class technology and sticky recurring service revenue. In that context, we are happy to see our services gross margins shift into positive territory with the transition from phase-in to full deployment of the airport security project complete. Having our services business become EBITDA positive is another milestone we are proud to have achieved. In fact, as a company, we had only a small nominal EBITDA loss for the quarter and look forward to shifting this into positive territory. We have all the confidence that we will achieve that goal this year. Regarding our benchtop NMR business, we are very happy about our sales and prospects within this business. We feel this group is on the right track, and we are focusing on growth and continued innovation. We have previously discussed that we are applying the advances of our 100 MHz product to our 60 MHz offering. We feel that this will improve our position in the market, providing us with higher performance products at more price points. We hope to release these new products towards the end of this year, yielding revenue growth via direct sales as well as future partnering opportunities. Our steadfast goal and commitment this year is to achieve positive EBITDA in the benchtop NMR business, as well as our other business units. We are working very hard to achieve this objective by cost reductions and revenue growth. To provide more detail on our security services business, as previously announced on January 11, we took 100% control of all the served airports ahead of the contracted March 31 turnover date. We're happy to report we have exited the phase-in period and are now in control of the basic services and maintenance of all 89 airports in Canada. The phase-in period involved our team hiring and training over 100 technicians and taking over all preventative and corrective maintenance services for passenger screening equipment at 89 airports in Canada from the incumbent service provider. We'll now focus on working through the backlog of additional projects and requirements that our customer has for us. With the reduction in ramp-up costs and training, this project began generating positive EBITDA in Q1 2024. We expect our margins to grow as we move to full run rate, and we'll continue to increase EBITDA throughout 2024 and beyond. Additionally, we continue to seek and evaluate other opportunities in our services business with existing and new customers, as well as partners in Canada and the United States. Regarding third-party equipment, sales have been steady in the past two quarters and expect them to remain so throughout the year. As mentioned on our last call, we believe the macro level concerns of headwinds regarding analytical equipment sales have lessened. Therefore, we expect this business to be stable throughout the remainder of 2024. Regarding Quad Systems' investment and our high-field NMR product initiative, we currently have two demonstration labs set up and working with full systems, including a superconducting magnet and our console, which we manufacture for Quad. There is one in Strasbourg and one in Zurich. There are plans to open more demo labs in locations such as UK, China, USA, and Calgary at our headquarters, as we see more customer traction and contingent on available cash flow. In addition to the demonstration labs, there are several paying customers using our high-field NMR products, and we have received positive feedback and testimonials from these customers. While the accounting structure between the two companies has changed, the relationship remains strong. Our team has been integral in developing the high-field NMR system. The two teams will continue to collaborate on an ongoing basis. Our Nanalysis sales team is authorized and trained to sell and service both the high-field system as well as separate modules in several territories. We remain very enthusiastic about the potential of high-field NMR product line, the associated market opportunity, and the relationship with Quad. We continue to own 43.5% of that company and hold two seats on their board of directors. In terms of medical imaging sales, we continue to make progress on completing a large customer MRI installation in Europe that includes our proprietary MRI console as well as third-party modules. Regarding new sales, we are encouraged that several large projects are expected to be in the pipeline in the coming quarters, and we will provide more information on those as it becomes available. Overall, in summary, I am very encouraged by our first quarter results, and this is after a strong Q4. In the past, it has been typical for Q1 to be weaker than Q4, but not this time, and I believe this trend will continue. We are starting to demonstrate what our scientific instrumentation products and services company can look like in terms of operating results. I want to emphasize, starting, we are not done yet. The changes we put into place are bearing fruit in both of our main businesses, benchtop NMR and security services. Our benchtop NMR business is doing well. We have good visibility, and we expect to continue to have an excellent 2024. Our advanced product offerings and potential collaborations will only bolster what our efforts have been to date. Our airport security services project has moved out of the rollout and will continue to grow into the full run rate with improving margins. We will look to optimize our workforce and leverage our trained services team. We look forward, in the not-too-distant future, to deploying our proprietary capabilities through this channel as well. ...Our overall financial objective remains to continue to drive down costs while increasing revenue steadily in 2024 and 2025, resulting in a sustainably profitable company. As always, I would like to thank our investors and our incredible employees for their support as we continue to execute on our mission and drive towards our grand vision. Operator, I'd now like to open up the call for questions. Thank you. Ladies and gentlemen, we will now conduct a question and answer session. If you have a question, please press star followed by the number one on your touchtone phone. You will hear a three-tone prompt acknowledging your request. If you would like to cancel your request, please press star two. Please ensure you lift the handset if you're using a speakerphone before pressing any keys. One moment please, for your first question. Your first question comes from the line of Stefan Quenneville from Echelon Capital Markets. Your line is now open. Hey, guys. Thanks for taking the question, and congrats on the great quarter. Really nice to see the substantial progress you guys made. Can I just first ask about, I guess, the CATSA business and I guess the full revenue? That's a really big number, and it's been, you know, really helped you guys, I mean, a nice beat on the quarter. And you say, you know, it's gonna fluctuate. Can you kind of dive into that a bit? Like, what's driving that number? Is that coming from the sort of special products you special projects you've talked about, that you want to implement with them, and you have to, you know, get some parts to do that? Or is it parts going in sort of after the busy Christmas travel season, so you see a big bump up in Q1? Just maybe help me understand whether there's a seasonality to this or really it's just sort of a random thing you, you can't really predict too well. Hey, Stefan. Randy here. Yeah, there's a number of factors that drive that piece. It can be consumption of parts, as you say, in a busy season. It can be requirements from the customer that they want to stock up on certain items. There's minimum and maximum part levels that we ensure we're maintaining for the customer. So all of those pieces go in. Of course, if you've got projects, you can see more coming along as well. Bunch of factors there. I think it's, you know, key that, you know, looking at Q4 over Q1, in fact, we actually still had incremental improvement on revenue quarter-over-quarter, even when removing those parts. So, while it did give us a big boost here in Q1, it was really quite a good quarter even without. Okay. And do you still foresee sort of sequential growth in the business through the balance of the year? Or because of the sort of aberrationally high parts, so that might not occur. Like you might have a sort of you know... Well, I mean, you pulled through some of that part revenue from Q2, Q3. Yeah, I think that's entirely possible. So, you know, that was a very significant amount of parts revenue- Yeah this year. So we've broken it out so that it's very clear that, you know, the underlying services that we're providing are in the security service revenue line. And, I would encourage everyone to take a look at the MD&A, where we detail this out. And, and then, of course, we have product sales. So I think I, I would certainly focus on, on growing those two revenue lines through the year, because that's what's really contributing margin to the business. That's great and very helpful. Thanks for breaking that down actually. You know, makes it a little much clearer. So just talking a bit, moving to the, I guess, the product revenue. Again, a really strong quarter, you know, much stronger than my expectations on benchtop NMR. Can you talk about what's going on there? You kind of highlight a strong pipeline. Just, you know, what's going on with you guys on a more granular level? And maybe if Sean wants to chime in a bit, I don't know if he wants to keep some of the details a bit private, given the competitive nature, but talk a bit about the enhancements you're talking about in sort of towards the back half of the year on the products and how you think that's going to impact just your competitive dynamic in the market. And what it might do for sales and when we're gonna see those products? Sure. Thanks, Stefan. I'll handle the... Sorry, go ahead, Sean. Take care of that one, and then I'll jump in on the financials afterwards. Sure. Yeah. So we'll, yeah, you know, in our industry, there's certain flagship performance metrics that are important when a customer makes a decision. And, you know, we feel like we've nailed it with the 100 MHz. And we made several important technology innovations, including receiving some United States patent grants with that product. And we're gonna be applying those to our 60 MHz product, to be able to tackle a certain segment of the market that we should improve in. And then in addition to that, we feel like it's gonna open up certain partnering opportunities. And we know that based on detailed discussions we've had, regarding partnerships. And so, you know, we expect to to expect to start shipping commercially these enhanced versions of our 60 MHz by the end of the year. And then before I let Randall jump in, with regards to the continued steadiness of the benchtop NMR sales growth, it's just a matter of execution. There's nothing, nothing magic going on there. It's... As we've discussed, quite, quite significantly in the past, we had some turbulence in our, in our company because of acquisitions, and we've worked really, really hard to fix those. And now we just feel like we're executing correctly. Great. Thanks, Sean. I, I don't know if I have a ton to add from the financial side. I'll just reiterate what we said in the press release, which was, you know, we've had significant year-over-year improvements in our benchtop NMR over Q1 of 2023 of CAD 1.3 million. And, you know, that's really ten, you know, a result of what Sean just mentioned. Okay. No, that's great. And, you know, I just wanna make sure I understand your guidance too, on that business. You're targeting EBITDA breakeven for the, you know, products this year. Is that what you specifically said? The whole business. So, if you look at our segment note in the financials, both the scientific equipment and security services segments did positive adjusted EBITDA in the quarter or income- Yes. Before other items. So, you know, now it's a matter of accelerating that a little bit further to cover our remaining corporate costs. Okay. Yeah, thanks for that. And then just finally, I don't know if... I know Sean's talked about this in the past. I'd just like to hear a little bit more about it, and I don't know what he can sort of share on the call. But in terms of those vertical partnerships, you know, with the enhancements to the 60 megahertz, which I think, you know, there's gonna be obviously some performance enhancements as well as I imagine some, maybe some price point enhancements to make it more appropriate for certain more widespread use. I'm not exactly sure. Do you wanna just talk about what maybe those types of partnerships might look like, when they, you know, might be announced, and then when, you know, from the announcement of those types of deals, when we might see real flow-through to revenue in the benchtop business? Sure. Yeah, thanks for that question, Stefan. So, as most of you know, we currently sell our products into many different vertical markets, like pharmaceuticals or petrochemicals or advanced materials or food. And then, of course, we sell a lot into academia as well. And so, that fact is because of the intrinsic nature of magnetic resonance being applicable to all these different vertical market applications. And, you know, and I left it out, but I'll mention another one. You know, correct detection of illicit drugs, where other techniques might miss a synthetic opioid, for example, because some clever chemist tweaked a molecule, and it's not on an existing forbidden list, but it's a deadly synthetic opioid, right? So magnetic resonance is particularly good at those types of applications. So the evolution of our company is to, yes, to continue to sell our benchtop NMR products as sort of general-purpose analyzers. And, you know, our customers use our products today to analyze different types of things. But going forward, what we wanna do is also focus in on particular verticals. So with branding and with applications, for example, we would go deep in the food vertical, right? And that product would be, it'd be visibly clear that that was a food analyzer and not an illicit drug analyzer, and so on. So those types of vertical market initiatives would be with partners, you know, companies that have been in the food testing industry for, you know, 80 years, and have deep channels in that particular vertical. So that's what I'm referring to when I talk about these partnering discussions that have been ongoing and that, you know, we've come close a couple of times to doing deals like this. But just sort of, you know, just haven't quite got over the finish line yet, and of course, we're gonna continue to persevere till we succeed. And then what that will do is, then you're gonna see a big step change in our revenue, and then growth from that new base of benchtop NMR. So that's why we would wanna do a deal like that, and that's the impact that it would have on our benchtop NMR revenue. Just to be clear, that's more of a 2025 and beyond type of thing. Is that fair to say? Discussions are ongoing, and, you know, we're interested in doing these deals as, you know, as soon as we can. I will say that it's likely that any deal along these lines would be contingent on these product advancements that we've been talking about, for a myriad of reasons. One of them being that, you know, our current 100 megahertz product has, you know, incredible performance, but it also has a very high price point. So some of these vertical market strategies require a product that has formidable performance, but also is, you know, let's say, instead of having an end user price of $150,000, you know, maybe has an end user price of sort of $85,000. So, price is part of the consideration as well, when you start talking about partnering and more specific branding and going deeper with larger volumes in a vertical. So, 2025 is a reasonable expectation, but, you know, I'm pushing these things every day. Of course. Okay, that's great. And just one last little question on the medical, I guess, contracts you're working on that you think are gonna come in the next few quarters. Can you give a little more color on that as well? ... Sure. You know, so, our proprietary technology platform, especially the electronics and the low-level software, like the software with all the, the mathematics and the physics in it, is in all of our products. It's in our benchtop NMR products, but it's also in our MRI products, as well. And, and on the medical imaging side of our, our business, we use that technology, as a standalone product that we sell. We call that our MRI console. But we also, bid on projects that involve third-party modules, and we use our technical expertise, to, to integrate those, those modules together. And then, for example, in, in this particular project in France, it's about a CAD 1.2 million total sale. And, and there's been some milestones that have progressed along the way. We expect that to complete, or I expect that to be completed this quarter. There has been, and I don't want to get into details, nor will Randall, but there has been some revenue recognized on that project already. But there's still some remaining amount. In addition to that, there are other medical imaging sales that we expect to close this quarter, and, you know, they're... I'll call them sort of lumpy in nature because of the price tags. They tend to be quite high. But nevertheless, they're part of our, you know, our imaging equipment expertise and proprietary technology, and you'll hear more about those in the coming quarters. And, you know, we expect some evolution in that part of our business. You know, I don't call it sort of our core business, but it is some, we're leveraging our core capabilities to generate that kind of revenue, and I anticipate that part of our business to evolve a little bit. And there are also the possibilities of some exciting partnerships in that part of our business as well, going forward. And that's, you know, we go through that part of our business on our path towards our grand medical imaging vision, which I've articulated in the past. Great. Thanks for that color. That's it for me. A great quarter, guys. Thanks, Stefan. As a reminder, if you have a question, please press star one on your telephone keypad. Your next question comes from the line of Christopher Pu from Canaccord Genuity. Your line is now open. Hello. Yeah, it's Chris calling in for Tania. A great quarter, guys. Yeah, I just have a few questions regarding the cost outlook for the parts. I'm wondering if you could provide an update on that, your outlook on that. In terms of our product sales? Yeah. Cost of goods sold, Yeah, like the material costs and for the parts, yeah. Sorry, just a quick... Chris, can you, Chris, can you just clarify that? I'm still, before Randall gives you an answer, can you clarify if you're referring to the parts flow-through in our services business, or if you're referring to our, basically our, our COGS and our gross margins on our product business? Please clarify. Yeah, sure. So in the Q4 results, there was mention of inflation still impacting the parts. I'm just kind of wondering, how do you see perhaps the impact of inflation going forward? And I- Well, I think- Yeah. Go ahead. Yeah. No, no, go ahead. Yeah. Well, I think, you know, there was significant inflation through the post-COVID period, particularly with certain types of parts and things required, you know, with semiconductors and that type of thing, as we all remember. And, because we use a weighted average costing model, the cost inflation around parts like that can have a long-lasting impact, in our actual cost of goods sold. So as inflation comes down, we start to average down those costs of materials. Now, you know, inflation is cooling. It's still getting down, towards kind of where we would expect benchmark to be. So we're likely expecting that to start to level off. You know, through the past couple of years with inflation at high rates, certainly it was impacting our average cost, and it's gonna take some time for that average to come down. Okay. In regards to the manufacturing capacity, I'm just kind of wondering, currently, what's your estimated% utilization of your manufacturing capacity for your scientific- That's a good question. ... equipment? Yeah, it's a good question. You know, I think where we're at today, we've got, you know, we've worked hard over the last year to get our manufacturing capacity in line with our, with our kind of revised expectations of product manufacturing and sales. We've got capacity right now that I think is well lined up with our forecasts, as well as in terms of reasonable utilization and hours available. But with enough ability for us to be able to expand our capacity, you know, if we do have a particularly good quarter or as seasonality impacts, we take all of this into consideration when we're planning our workforce. Okay. Sounds good. And my last question is regarding your cost initiative. I know, like, your company's really focused or laser focused on reducing, I guess, overhead and becoming more efficient. And there was something in your documents about, you know, you're beginning an additional cost reduction plan for the scientific equipment segment. So, you know, after accounting for that, like, how close would you say that your company is to achieving, like, the optimum resource level? I think we're getting closer. I think there's still work that we wanna do, which is why the plan is ongoing. And it's not just necessarily about resources too, but looking at overhead, looking at, you know, how we run the business to make sure that, you know, it's every dollar we spend is contributing value back. And as we continue to go down that path, you know, the goal ultimately is to push those margins, you know, back up to historic rates, or as close to as we possibly can. So, you know, we're continuing to work on that. We're analyzing every day, whether it's, you know, efficiency, whether it is, you know, utilization as we just talked about, or whether it's, you know, where are we putting our overhead dollars. All of that continues to be on the table and something that we look at closely and, you know, and, and we're still not... We're still working through it, and still working towards, our end goal. Okay. That's great. Yeah, that's all for me. Yeah, congrats on the great quarter. Yeah, thanks very much. There are no further questions at this time. I will now turn the call over to Nanalysis CEO, Sean Krakiwsky. Please proceed. I'd like to just thank everyone for joining the call, and, you know, we're really excited about our business going forward. You know, we look forward to the next opportunity to talk about our business with you. So thank you very much and have a wonderful afternoon and evening. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.